Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors. Elevated levels of serotonin contribute to the gastrointestinal and possibly other symptoms experienced by these patients.

In addition to LX1032, Lexicon has three other drug candidates progressing through various stages of clinical development, including LX1031 for irritable bowel syndrome, LX2931 for rheumatoid arthritis, and LX4211 for diabetes. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

"This is an important study, designed to evaluate LX1032's effect on the gastrointestinal symptoms experienced by patients with carcinoid syndrome who have become refractory to current treatment options," said Philip M. Brown, M.D., J.D., senior vice president of clinical development at Lexicon. "We are encouraged by the clinical results obtained to date in which LX1032 demonstrated potent reductions in serotonin production in healthy volunteers."

The Phase 2 clinical trial is designed as a four-week, randomi
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...f ultrasmall transistors and more powerful compute...g nanowires are closer to reality after a key disc... the University of California at Los Angeles. , ...es with layers of different materials that are sha...cal requirement for making efficient transistors o...
(Date:11/25/2009)...-- Biotech firm Replikins Ltd., which has analyzed...ic through the prediction, outbreak, and progress ...est biochemical analysis of the virus. The new dat...") virus has dropped from its peak of 3.7 (s.d. 4....ng of 2009 to resting non-epidemic levels this wee...
(Date:11/25/2009)...re/--Formanybusinesses,2009hasbeenapainfulyear.Not...ngnetworkofexpertphysiciansspecializingexclusively...wnthenumberof physiciansinitsnetwork sinceNove...dmorephysician-ownedcenters,includingoneinPuertoRi...gicMDhasopened13newbioidenticalhormonespecialtypra...
(Date:11/25/2009)...wire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a leadi...oday that it executed,a joint venture (JV) agreeme...y Co., Ltd. (Sinovac Dalian). The JV will research...cines. Sinovac will contribute its expertise,and e...class vaccines; the,other party will bring its lan...
Breaking Biology Technology:Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3
...ent Results in Improvements in Physical ...AN FRANCISCO, Oct. 27 More than half of patients,...of golimumab (CNTO 148),50 mg and 100 mg, an inves...ents in the joint and skin symptoms of active psor...stained through one year.,Golimumab-treated patien...
...apeutics,(Nasdaq: FOLD ) will announce third quar... of markets on Monday, November 3, 2008. The resul...nce call and webcast that,afternoon at 5 p.m. ET.,... the conference call at,5 p.m. ET by dialing 877-4...al). A telephonic replay of the call will be avail...
...FirstCall/ -- China Medical,Technologies, Inc. (th...ed,medical device company that develops, manufactu...ucts today announced that it will report selected,... revenues, net income and,earnings per ADS for the...2Q FY2008") on November 18, 2008 and full unaudite...
Other Biology Technology:One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 2One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 3One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 4One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 5One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 6One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 7One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 8One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 9Amicus Therapeutics Announces Third Quarter 2008 Results Release Date 2China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries 2China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries 3
(Date:11/25/2009)...he heart pumps some 250 million liters of blood th...e fibers of the heart have to be extremely durable...uer, vice chair of the Department of Medicine III ... Dr. H. A. Katus), has discovered a protein that i...scular unit, the sarcomere. In cooperation with ot...
(Date:11/24/2009)...ors to understanding how sounds associated with Na...al or if they hear it at all. , The same type o...uses to detect flaws in the space shuttle,s behemo...o peek inside the giant head of a whale. The scans... of a whale,s hearing anatomy using a breakthrough...
(Date:11/24/2009)...er 24, 2009) -- The Wildlife Conservation Society ...last remaining population of Siberian tigers has l...e of poaching and habitat loss. , WC...ls of what needs to be done to protect remaining p... The report was released by the Siberian Tige...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Rocket science leads to new whale discovery 2Report shows dramatic decline in Siberian tigers 2Palatin Technologies Inc to Report Fourth Quarter and Fiscal Year 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13859 1Palatin Technologies Inc to Report Fourth Quarter and Fiscal Year 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13859 2Delcath Systems to Present at Rodman 26 Renshaw 11th Annual Healthcare Conference 56246 1Mindray DS USA Appoints Michael Thompson Vice President of U S Ultrasound Sales 56243 1Mindray DS USA Appoints Michael Thompson Vice President of U S Ultrasound Sales 56243 2Mindray DS USA Appoints Michael Thompson Vice President of U S Ultrasound Sales 56243 3
...in sequence data available, scientists are increas... of information that determines a protein,s functi...proteins differ, such information can also help sc...cientists at the U.S. Department of Energy,s Brook...program "to sort the informational ,wheat, from th...
...es plays a role in how our arms and legs develop a... bits of material once dismissed as genetic "junk,...Harvard University. , The research, available toda...ists understand whether bits of RNA called microRN...ment not just by strategically turning off gene ac...
...ationwide will today for the first time be able to...ch for genes that underlie a range of chronic dise...t and other common diseases have been providing bl... of a project hosted by The University of Manchest...re to study genes in chronic diseases. The project...
Other Biology News:Scientists develop protein-sequence analysis tool 2MicroRNA may have fail-safe role in limb development 2'Dating agency' boosts hunt for disease genes 2
...: Calf thymus Description: Topoisomerase I relax...by a transient breakage and rejoining of phosphodi...Topoisomerase I allows molecules to be differentia...esis (3) . Topoisomerase I is active in the absenc...
...: E. coli containing a clone of the human Topoisom...lters the topological state of nucleic acids by pa...k which generates a separate DNA helix (1,2) . As ...ism, the enzyme can relax negatively or positively...
...lymerase I catalyzes the template-directed polymer...rection. DNA Polymerase I possesses a 3?5 exonucle...ers the error rate during DNA replication, and als...es the enzyme to replace nucleotides in the growin...
...lease-free Klenow Fragment is a genetically engine...ease activity has been removed, leaving only the 5...uclease activity makes Exo- Klenow Fragment the en...DNA probes by the random primed method, and for DN...
Biology Products: